Xiangyong Liu - Betta Pharmaceut Co LTD

基本信息

浏览量：1

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 12 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

BPI-520105, a Highly Potent, CNS-penetrant 4th Generation EGFR Inhibitor Overcoming Major EGFR Resistance Mutations in NSCLC

Jing Guo,Lijia Liu,Xiangyong Liu,Bang Fu, Guangcan Bai,Changyong Qiu,Wei Ren,Xiaodong Song,Guolong Du,Xiao Sun, Yongchun Zhang, Weidong Cai, Pingping Wang,Haibo Chen,Xiaoyun Liu,Zhengyao Zou,Jiayu Zhao, Xuepeng Jv,Hong Lan,Lieming Ding,Jiabing Wang

Cancer Research（2024）

引用0浏览0引用

Discovery of a Potent Small Molecule MALT1 Protease Inhibitor for the Treatment of Cancer

Yuzhen Zhou,Bang Fu,Jie Chen, Weidong Cai,Xiao Sun,Yinlong Li,Wei Ren, Qichao Shen,Guolong Du,Xiaojun Zhou,Zhengyao Zou,Haibo Chen,Xiaoyun Liu,Cheng Yang,Xiangyong Liu,Jing Guo,Hao Wu,Lieming Ding,Jiabing Wang,Hong Lan

Cancer Researchno. 6_Supplement (2024): 7583-7583

引用0浏览0引用

BPI-452080: A Potent and Selective HIF-2α Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma, Von Hippel-Lindau Disease, and Other Solid Tumors

Pingping Wang, Rongwen Yang,Yun Sun,Xuepeng Ju,Jiayu Zhao,Yanju Liu,Xiaoyun Liu,Zhengyao Zou,Jialin Ren, Min Wang,Haibo Chen, Xuegang Yi,Jian Zhang,Teng Ma, Gaoliang Cheng,Lijia Liu,Jing Guo,Xiangyong Liu,Hong Lan,Lieming Ding,Jiabing Wang

CANCER RESEARCHno. 7 (2023)

引用1浏览0引用

Discovery of BPI-460372, a Potent and Selective Inhibitor of TEAD for the Treatment of Solid Tumors Harboring Hippo Pathway Aberrations

Hongling Shen,Xiaofeng Xu,Hongfei Rong,Xizhen Song, Jinheng Gao,Jie Chen,Di Zhu, Xiangdong Zhao, Jun Tong,Zhengyao Zou,Xiaoyun Liu, Jin Guo, Yan Xu,Yabin Li,Xiangyong Liu,Hong Chen,Jiayu Zhao, Yanju Liu,Xuepeng Ju,Haibo Chen,Hong Lan,Lieming Ding,Jiabing Wang

Cancer Researchno. 7_Supplement (2023): 501-501

引用3浏览0引用

Discovery of BPI-221351, a Potent, Selective, Orally Available, and Brain Penetrating Dual Inhibitor of Mutant IDH1/2

Hongling Shen,Xiaofeng Xu,Yabin Li,Xizhen Song,Jie Chen, Yunting Bi, Jing Guo, Tong Xu,Huijuan Zhang,Lijia Liu,Zhengyao Zou,Jialin Ren, Jun Tong,Xiaoyun Liu,Hongfei Rong,Teng Ma,Chao Wang,Xiangyong Liu,Hong Chen,Jiayu Zhao,Xuepeng Ju,Haibo Chen, Haidi Shen,Hong Lan,Lieming Ding,Jiabing Wang

Cancer Research（2023）

引用0浏览0引用

BPI-361175, a 4th Generation EGFR-TKI for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

Lijia Liu,Changyong Qiu,Xiangyong Liu, Yuanyan Lian,Haibo Chen,Xiaodong Song, Qichao Shen,Guolong Du,Jing Guo,Dan Yan,Hong Lan,Lieming Ding,Jiabing Wang

Cancer Researchno. 12_Supplement (2022): 5462-5462

引用5浏览0引用

BPI-371153, an Orally Bioavailable Small Molecule PD-L1 Inhibitor

Yiqian Wang, Xiangyan Jing, Hong Chen, Huijuan Zhang,Tianyi Ma, Yao Zhang,Chunhui Zhang, Guangzhi Zhang,Xiangyong Liu,Dan Yan,Jing Guo,Hong Lan,Jiabing Wang,Lieming Ding

Cancer Researchno. 12_Supplement (2022): 5444-5444

引用0浏览0引用

BPI-442096: A Potent and Selective Inhibitor of SHP2 for the Treatment of Multiple Cancers

Ling Li,Bang Fu, Han, Zhongxin Sun, Xiangdong Zhao, Xuepeng Jv, Jun Tong,Jiayu Zhao,Zhengyao Zou,Haibo Chen,Xiaoyun Liu,Wei Ren,Yinlong Li,Wenmao Wu,Jing Guo,Dan Yan,Xiangyong Liu,Hong Lan, Hao Wu,Lieming Ding,Jiabing Wang

Cancer Research（2022）

引用2浏览0引用

BPI-23314: A Novel Orally Bioavailable Small Molecular BET Inhibitor with Target Protein Degradation Activity

Jing Guo, Yan Xu,Dan Yan,Bo Yu, Weiwei Yu,Haibo Chen,Xiaofeng Xu,Xiangyong Liu,Hong Lan,Lieming Ding,Jiabing Wang

CANCER RESEARCH（2020）

引用0浏览0引用

BPI-28592, a Next-Generation TRK Kinase Inhibitor That Potently Inhibits Primary and Resistant NTRK Mutations

Bang Fu,Dan Yan,Lingling Liu,Jing Guo,Jisheng Huang,Tianyi Ma,Yinlong Li,Wei Ren,Jie Chen,Xiangyong Liu,Hong Lan,Lieming Ding,Jiabing Wang

Cancer Research（2020）

引用1浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn